Anti-CD20 monoclonal antibodies: reviewing a revolution
Human Vaccines & Immunotherapeutics, 2018 Since the inception of rituximab in the 1990s, anti-CD20 monoclonal antibodies have revolutionised the treatment of B cell hematological malignancies and have become a cornerstone of modern gold-standard practice.
J. M. L. Casan +3 more
doaj +1 more source
Prognostic Implication of Semi-quantitative Immunohistochemical Assessment of CD20 Expression in Diffuse Large B-Cell Lymphoma [PDF]
Journal of Pathology and Translational Medicine, 2016 Background: Immunohistochemical demonstration of CD20 in diffuse large B-cell lymphoma (DLBCL) is prerequisite not only for the diagnosis but also for assigning patients to rituximab-containing chemotherapy.
Chang Hwan Choi +8 more
doaj +1 more source
CD20 expression in the transplanted kidney of patients with graft loss and transient allograft dysfunction [PDF]
Journal of Medical Biochemistry, 2012 This study aimed to explore the relationship between the infiltration of CD20+ B cells and the survival time of a renal allograft and to investigate the role of infiltrated B cells in the rejection of the renal allograft.
Han Yong +7 more
doaj
Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: A report of three cases [PDF]
, 2017 Hairy cell leukemia variant (HCLv) is a chronic lymphoproliferative disorder classified as a provisional entity in the 2016 WHO Classification of Lymphoid Tumors.
Berno, Tamara +12 more
core +1 more source
eJHaem, 2022 The prognostic effects of the CD20 positivity have been studied extensively in B‐lineage acute lymphocyte leukemia (B‐ALL) patients, but the results remain controversial.
Yun Tian +7 more
doaj +1 more source
Novel chimerized IgA CD20 antibodies: Improving neutrophil activation against CD20-positive malignancies [PDF]
mAbs, 2020 Current combination therapies elicit high response rates in B cell malignancies, often using CD20 antibodies as the backbone of therapy. However, many patients eventually relapse or develop progressive disease. Therefore, novel CD20 antibodies combining multiple effector mechanisms were generated.
Mitchell Evers +12 more
openaire +8 more sources
FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy
OncoImmunology, 2018 Diminished overall survival rate of non-Hodgkin lymphoma (NHL) patients treated with a combination regimen of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) has been recently linked to recurrent somatic mutations activating
Beata Pyrzynska +18 more
doaj +1 more source
B cells are capable of independently eliciting rapid reactivation of encephalitogenic CD4 T cells in a murine model of multiple sclerosis [PDF]
, 2018 Recent success with B cell depletion therapies has revitalized efforts to understand the pathogenic role of B cells in Multiple Sclerosis (MS). Using the adoptive transfer system of experimental autoimmune encephalomyelitis (EAE), a murine model of MS ...
Archambault, Angela S +5 more
core +3 more sources
Development of a Bispecific Nanobody Targeting CD20 on B-Cell Lymphoma Cells and CD3 on T Cells
Vaccines, 2022 B-cell lymphoma is a group of malignant proliferative diseases originating from lymphoid tissue with different clinical manifestations and biological characteristics.
Yanlong Liu +8 more
doaj +1 more source
MicroRNA-155 influences B-cell function through PU.1 in rheumatoid arthritis [PDF]
, 2016 MicroRNA-155 (miR-155) is an important regulator of B cells in mice. B cells have a critical role in the pathogenesis of rheumatoid arthritis (RA). Here we show that miR-155 is highly expressed in peripheral blood B cells from RA patients compared with ...
Alivernini, Stefano +13 more
core +2 more sources